Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Glucose Intolerance During Pregnancy Associated With Postpartum Cardiovascular Risk - (DGNews)
    TopAbstracts in Diabetes 12/01/2009 - (DGNews)
    Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function - (N Engl J Med)
    TopAbstracts in Diabetes 11/24/2009 - (DGNews)
    TopAbstracts in Diabetes 11/17/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
      Clinical Practice In Type 2 Diabetes: After Metformin And Lifestyle, Then What?
      Diabetes and the Heart: Diabetes and Glycemic Control - Endocrine
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiometabolic Screening and Hospital Care
      Diabetes and the Heart: Diabetes and Glycemic Control - Cardiovascular

      Webcasts/CME archive

       Recent cases - Diabetes
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Antibody Response To Insulin Lispro Similar To That To Recombinant Human Insulin

        A DGReview of :"Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes."
        Diabetes Care

        01/06/2003
        By James Adams


        Patients with type 1 or type 2 diabetes treated with insulin lispro have immunogenic profiles similar to those of patients treated with recombinant human insulin.

        Insulin lispro does not induce significant levels of specific or cross-reactive antibodies in patients who have previously received insulin, and there are no significant antibody-dependent increases in the required dosage of insulin for these patients.

        Allergies to insulin are no more common among patients treated with insulin lispro than among patients treated with recombinant human insulin.

        These results are from a multinational, multicentre combination of controlled and non-controlled, open-label studies conducted over a 4.5 year period. They are reported by investigators from the Department of Medicine at Indiana University School of Medicine and Lilly Research Laboratories of the Eli Lilly Company, both in Indianapolis, Indiana, United States.

        The study included 1221 men and women, aged 12 to 81 years, with type 1 or type 2 diabetes. Radioimmunoassays were used to assess levels of circulating anti-insulin antibodies.

        Results showed that the levels of insulin-specific and lispro-specific antibody responses were within background levels of the assays.

        In patients who had previous exposure to long- and short-acting insulins, transfer to lispro did not increase antibody levels significantly above baseline.

        New exposure to insulin lispro did increase cross-reactive, but not specific, antibody levels.

        Antibody responses decreased over time and returned to baseline or near-baseline levels by the end of the study period. There was no evidence of anamnestic antibody response in any patients treated intermittently with insulin lispro.
        Diabetes Care 2003; 26(1): 89-96. "Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send